Clinical Trial

Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Study acronym: STAR
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 6, 2026 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-19; most recent amendment 2026-03-04.
Status change: Not Yet Recruiting → Recruiting 2025-07-06
Trial Details
NCT Number NCT06895031
Lead Sponsor Guangzhou JOYO Pharma Co., Ltd
Conditions Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Enrollment 210 participants
Start Date 2025-03-31
Primary Completion 2026-03-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-06